Mohammed Haneefa Nizamudeen/iStock via Getty Images
SELLAS Life Sciences (NASDAQ:SLS) traded sharply lower on Thursday after the New York-based biotech released interim results from its Phase 3 REGAL trial for its lead asset, galinpepimut-S (GPS), which is targeted at the blood cancer acute myeloid leukemia.
According